Loading stock data…
Veracyte (VCYT)
$60.46-0.03 (-0.05%)
Market OpenUpdated 3:03 PM EDT
Veracyte, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veracyte, Inc. in the Healthcare sector is trading at $60.46 with a market capitalization of $4.1B. Wall Street consensus targets $49.10 (10 analysts), implying a -18.8% move over the next 12 months. The stock is currently near its 52-week high of $60.83, remaining 54.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -18.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $139.07M↓ | $140.64M↑ | $131.87M↑ | $130.16M↑ | $114.47M |
| Gross Profit | $101.16M↓ | $101.97M↑ | $91.28M↑ | $89.77M↑ | $79.51M |
| Operating Income | $22.65M↓ | $39.91M↑ | $23.11M↑ | $14.31M↑ | $2.90M |
| Net Income | $28.71M↓ | $41.15M↑ | $19.14M↑ | -$980,000↓ | $7.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.55%
Volume
Today's trading volume
766,491
Recent News
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.
This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.
Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.
Dow Jones Futures: Techs Rebound, SpaceX Rises Despite Trump's Iran Threat; Warsh's Fed Debut Due
Tech futures are rising modestly despite President Trump's threat to resume bombing Iran. Fed chief Kevin Warsh's comments loom.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call
Veracyte’s latest analyst update comes with no change in the price target, which can be just as informative as a revision. With fresh information in hand but no shift in the target, the message for you as an investor is more about stability than surprise. Read on to see how to interpret this kind of unchanged call and how to keep tracking the story as the narrative around Veracyte continues to evolve. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies...